Consistent with these studies, we found that triclabendazole treatment induced the GSDME-NT fragment generation and lytic cell death in breast cancer cells which could be partly reversed by caspase-3–specific inhibitor Ac-DEVD-CHO treatment, indicating that the production of GSDME-NT was mediated by active caspase-3. The gene discussed is CASP3; the disease is breast carcinoma.